NewGenIVF Group Limited exchanged existing convertible notes and related warrants held by an institutional investor for a new senior convertible note with an aggregate principal amount of $7,105,468.75. The transaction closed on August 14, 2026, following the execution of an Amendment and Exchange Agreement on August 11, 2026. This restructuring eliminates a mandatory proceeds sweep requirement that previously obligated the company to apply significant percentages of new capital raise proceeds to prepay debt under a June 2026 agreement. The new note includes a leak-out framework restricting the investor's sales of shares issuable upon conversion and other modified terms designed to provide greater flexibility for future financing activities. NewGenIVF Group Limited operates in real estate development, digital asset innovation, and reproductive health solutions.